1. Home
  2. RXO vs IRON Comparison

RXO vs IRON Comparison

Compare RXO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$19.82

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$69.50

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
IRON
Founded
2022
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.3B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
RXO
IRON
Price
$19.82
$69.50
Analyst Decision
Hold
Strong Buy
Analyst Count
14
11
Target Price
$16.38
$103.18
AVG Volume (30 Days)
1.6M
313.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
72.81
N/A
EPS
N/A
N/A
Revenue
$5,742,000,000.00
N/A
Revenue This Year
$0.49
N/A
Revenue Next Year
$6.90
$283.52
P/E Ratio
N/A
N/A
Revenue Growth
26.20
N/A
52 Week Low
$10.43
$40.00
52 Week High
$19.59
$99.50

Technical Indicators

Market Signals
Indicator
RXO
IRON
Relative Strength Index (RSI) 80.01 56.24
Support Level $16.07 $57.79
Resistance Level N/A $69.36
Average True Range (ATR) 0.91 2.57
MACD 0.48 0.64
Stochastic Oscillator 90.49 62.61

Price Performance

Historical Comparison
RXO
IRON

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: